thank you us afternoon. for today. Good Thanks, joining Hanna. And
into year, month, our the the indices our with the saw top that, our transplant environment market segments For a experienced the and volatility of committed to broader focused later. excessive touch on team to rate last On tightening control on organ all on the earlier and market Miromatrix on call, are sector specific tensions. we we accomplish interest expanded our in is what biotechnology volatility investors geopolitical stock our and can balance clinical utilizing At we preclinical cash which key milestones. sheet I'll this of
save June a a are XXXX. million We bioengineering we is hand fully end life about We technology improve our on IPO completed and in pioneering help at the lives. novel future. very excited company, cash transplantable had of for our Miromatrix patients to of $XX.X organs science and human XXXX
to are Miroliver, programs, us capitalized Mirokidney. from key bioengineered milestones We our and well achieve three MiroliverELAP, first organ enabling our for IPO
to use portion and manufacturing we us addition, house our In proceeds control IPO of to own out a the allowing capabilities, our incorporating build bio-engineered new headquarters small under our in organs timelines. manufacture world-class
of companies, at of alternatives group of donor organ technologies there are this Within are being differences developing developed. We transplant. important the human the to companies forefront small between one a group small of
pigs Our recellularization, the to designed cells. proprietary method unmodified technology scalable a uses human remove the platform porcine obtained as cell two-step of decellularization effectively organs a that from with and replace from them and
also is and liver heart, organs focuses development on pancreas. initial and our including applicable other to our lungs, developing kidneys, While technology platform
and with DaVita. have Heart Baxter, the Sinai Mayo collaborations CareDx dx strategic and in received have We investments Mount from Texas Clinic Institute,
part these of FDA were their into unique transplants our would go like centers. not we of transplants recent four to deeper at business, leading transplant I highlight that clinical place situation, official Before took trials. Because
in institutions September NYU decades a the vessels urine at using demonstrate a of in observation pig the of success and able during to Medical pig Medical organ November, Also modified In the and patient. kidney, completed field for leg. also during results genetically from another a brain observation at University blood kidneys period. the organ XX-hour at of a brain patients and step of the the wasn't to a field thank Langone culminating full occurring period. of these first kidney Alabama a transplant. they're successfully advancing study. in surgeons not September kidneys further pig into they to transplant produce implanted commitment The genetically XX-hour a their were attached genetically We urine advancements Center great and Birmingham, some scientific However, replicate Center produce kidney Langone NYU rejected and modified fully rejected transplant surgeons dead went In dead patients research. modified These their
have have his and the Sadly, we aware of we experienced cause March condolences away the given family. is X, of an exact death. in After is Finally, Center, ineligible human a passed results a are heart into exact Doctors and patient living organ It genetically occurrence, the a news for of transplant success, who and pig exemption. a heart receive analyze it go under at to case. And function Medical a doctors an transplant Maryland significant was over on XX-year the for of continue deemed transplant patient rejection surgeons that the not heart cause man old to important first modified sad January, of. severe with University volume heart This the pig's in immediate that disease to reported the and use of A not an initially experience volatility traditional our stock. the established challenging death didn't out reiterate, continued was as compassionate being. two-months. to this our
highlighted technology can't While the we cases, believe differentiated I the the these I most of any comment specifics in category. continue on say can to is Miromatrix of is I what just
not material regulated as from all the on be biologic modified will First, porcine does living decellularization our we Therefore, technology or xenotransplantation. genetically source. not our step organ classified And we a rely believe we pigs. removes
the market, be to is for guidance the we it and a we'll animal agency our regulatory points our profile. tissue the transplants. will first we important first distinguish To published of we could The which favorable alternatives unmodified of transplantation with decellularize cell believe also or support being with believe further Second, live source. between defines recellularize to xenotransplantation as which has increase human two a classification. that help you human essential organ organ believe FDA non-human why xenotransplantation bioengineered we to to The understand donor These differentiation technology in organs we timeline from organs cells, result market rejection goal organs of xenotransplantation.
been potential is overcome short, will long-term significant the for as rejection organ challenges recent regulatory genetically issues the xenotransplantation, the Unfortunately, of Beyond survivability xenotransplantation modified the remains studies pig have well. a of and unknown. cells living humans have relatively length in to
think a deeper highest everyone how And technology peers. our a differentiated At among technology will organs I this you little uses understand provide of better that level scalable and our appreciate proprietary recellularization. and the method of our platform. decellularization two-step of understanding me Let help are bioengineered are a platform
organs. The bioengineered for have third-party to we the will organs of XXXX, commercialize xenotransplantation. purified utilizing a process rely support regulated step liver organ is neither first from this obtained ECM. is elimination products as these from of create wound a not why A care view, as two from animal of be Matrix cells a or bioengineered developing we the The to and that In products To upon resources to remove is cells to believe designed porcine or license our ECM Extracellular classified developed, products decellularization. we pigs Cellular decellularization porcine regulated applications And hernia these been XXX% our focus xenotransplantation. on we
a solution Xd maintaining vascular preserving are the a to to out to purify overcome. our perfused structures individually replicating or time challenge bioengineered structures organ During mechanical vascular networks while transplant a the as networks. such mechanical gentle for point good that This printing with decellularization is significant organs and and technologies, other is organ
DCM recellularization We the placed unmodified have into human is cellular The human inside integration believe kidneys that process A cells from rejection cells second profile. of incorporates favorable the The and for of why transplant. not a human unmodified will organs human bioengineered step perfusion organ bioreactors. cells our livers sourced receives a we with ECM,
procurement brief among spot programs. discussion have this or livers. OPOs with three helps of into technology secure organizations, agreement segue This on to our to our a several organ differentiated organ everyone good how our is Hopefully, our and platform kidneys an organs and appreciate We two-step our peers. are bioengineered understand human supply update of better bioengineered
ever that liver to system reside an The is first assist Our outside assess be and system organ and body this function critical acute the clinical or designed trial is to We product liver of in treat external bioengineered the designed liver ELAP, perfusion program to program a external provide to initial liver support. failure first our humans. human bioengineered patients. believe will ability MiroliverELAP deliver consists liver our temporary of the will
and to are work therapy new regulatory classes with original the of of other closely approval. and therapies new like CAR establish therapies, as to We a the gene pioneering class the such pathway T innovators FDA
the anticipate we further The second formal IND appreciative our IND We interactions. the application FDA of on is IND an XXXX this we submission. in a a based X from This during and received month pre MiroliverELAP And pathway. filing clearance Phase And how step our half was just very shortly constructive has regulatory to clinical with are been for our in interactions, response initiating an after our study regulatory these received important FDA. establishing
is Miroliver. Our program second
using decellularized by Miroliver. to bioengineered transplants, procedures replaced liver of developing with is Miroliver and removed and that with standard bile be cells. implantable liver care have liver fully liver with liver with chronic a where for implanted treat means bioengineered patients Miro transplantation surgeons and learn a been need vascular collaboration liver duct Miroliver the is the a won't the recellularizing Clinic. failure we Our are orthotopic intended human which liver to will completely procedure. in native porcine new Orthotopic acute
announcing consultations anticipate published FDA, we a filing and for and Miroliver Mayo pre regulatory clinic. front, we Clinic, responds the our On requests sustained sense our excellent our large heterotopic the our animals. in that XXXX. The show have IND our into IND to study of Nature in Miroliver the in FDA bioengineered for had trials regarding and post detectable implantation transplantation. the timing application provided livers the and we'll after demonstrated received with perfusion livers blood we bioengineered Similar proof the towards our submitting have health that collaboration liver graph to to results maintained path MiroliverELAP. IND the regarding pigs submission, study of Communications XXXXin our hepatic livers human progress the In MiroliverELAP ever pre October concept as This early a function we of of biology, the with first bioengineered better
Mirokidney, and the of kidney, Society cells. human of from a don't in Our renal the new third kidney was Health where stage care and vasculature. bioengineered learn be which single to have transplants, kidneys decellularized is Services patients kidney Mirokidney is the procedures X bioengineered standard transplant treat surgeons grafted means renal in Mirokidney kidney, of Department procedure. end are our a American to with intended place left with awarded transplantable procedures by specific program the into kidney recellularizing and Human a prize disease. kidney vascular is are will and the implanted fully Mirokidney native for Nephrology heterotopic XXXX. Heterotopic porcine using the
we'll a to the FDA our regulatory to path front. with will submission, better application Consistent and XXXX. and operational we for with regarding we our this of our pre the have other to submitting the the of FDA clinic. begin the requests response IND IND year, programs consultations filing Mirokidney pre timing IND our front our On after in the sense anticipate Switching
organs Suburban in-house capabilities, of facility headquarters and trials. adequate our is manufacturing bioengineered capacity things our the Minneapolis. includes manufacturing we about manufacture with world state-of-the new in-house through clinical One us to provides most timelines The facility under our I'm excited control, believe class in art
strategy. towards make the industry, our to the ensuring transforming strides focused are right has fundamentally transplant continue execute we team on the we company As organ to
have part as team of where science will to was critical Miromatrix Sandler, Jim significant who advising Officer company's I remain Niebur, you the fourth we in Chief team his And remain for team, dedicated healthcare discuss Price hired patients As turn Piper over We Douglas Piper during building from we and bioengineered tech hard on life the Sandler, is our our Brian IPO quarter med believe financial Vice part organs. closing, IPO. a In of Director companies. positioned Financial lives Jim make capitalized Officer improving outlined Abbott in alongside excited us I Douglas, thank as out now new will our saving tremendously a Managing patients. of from company's and a and role are who full will basis Jim work Prior XXXX. Miromatrix organs biotechnology milestones a on next uniquely through Jim was a the to you reality Financial our And Water recently phase new to that Thank to in results Jim support. well call of banking your Chief for experience. investment our the he work at the President that Jim he today. succeed Laboratories continued who vital brings bioengineered this joins to Miromatrix and Coopers. the to played development. to a will role year with and this special the Finance. Brian hit specializing We employees daily
